Long Term Extension Study in Patients With Primary Hyperoxaluria

Study Summary

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

Conditions

Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney Diseases Urologic Diseases Genetic Disease Primary Hyperoxaluria Type 3 (PH3)

Interventions / Drugs

DCR-PHXC

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment75 participants

Primary Completion—

Lead SponsorDicerna Pharmaceuticals, Inc., a Novo Nordisk company

Data Retrieved2026-04-11 02:55:47.366627+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.